January 10, 2012
Takeda Pharmaceutical announced on January 10 that the European Commission has approved revised package inserts for its type 2 diabetes treatment pioglitazone (brand name: Actos) and combination products containing pioglitazone. Statements specifying the drug’s benefits in second or third line...read more